NEWS THUR AH
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depression, and shortness of breath. The patent allows for multiple administration methods and dosing regimens, either alone or in combination with other active agents.
The patent is expected to expire no earlier than November 2042, providing extended exclusivity for MediciNova. The company is currently conducting a Phase 2/3 clinical trial in Long COVID in collaboration with University Health Network in Canada. MediciNova plans to initiate discussions with Health Canada for a New Drug Application if the RECLAIM study shows positive results.
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depression, and shortness of breath. The patent allows for multiple administration methods and dosing regimens, either alone or in combination with other active agents.
The patent is expected to expire no earlier than November 2042, providing extended exclusivity for MediciNova. The company is currently conducting a Phase 2/3 clinical trial in Long COVID in collaboration with University Health Network in Canada. MediciNova plans to initiate discussions with Health Canada for a New Drug Application if the RECLAIM study shows positive results.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment